We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 258

Sequestration impact on FDA uncertain

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • March 7 2013

Speaking during the Generic Pharmaceutical Association's annual conference in February 2013, Food and Drug Administration (FDA) Commissioner Margaret

Patentability of medical treatment claims to be heard by U.S. Supreme Court

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • June 30 2011

The U.S. Supreme Court has agreed to review a Federal Circuit Court of Appeals ruling that methods for determining the optimal dosage of thiopurine drugs used to treat gastrointestinal and non-gastrointestinal autoimmune diseases recite patentable subject matter under 35 U.S.C. 101

Life sciences company completes $1.5 million initial funding round

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • June 30 2011

Using technologies discovered at the University of Maryland, Plasmonix, Inc., a life sciences startup, has reportedly raised $1.5 million of a planned $2 million Series A equity financing

Ernst & Young issues 25th global biotech business report

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • June 16 2011

With research and development money growing increasingly scarce, Ernst & Young suggests in its latest Beyond Borders report that the traditional biotech business model may be under new pressures, but is still profitable

Financial group analyzes M&A deals in biotech and medical device industries

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • June 16 2011

According to an SVP Financial Group report, contrary to conventional wisdom, biotech exits occur faster than device exits and have lower, but solid, multiples on invested capital

Physician explores future of whole genome sequencing

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • June 16 2011

“The iconic $1,000 genome is very close to a realityat least in terms of reagent costs,” writes Eleanor Herriman, director of G2 Research and Analysis with Kennedy Information Inc., in a June 3, 2011, article for BNA’s Life Sciences Law & Industry Report

FDA releases nanotechnology guidance for regulated industries

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • June 16 2011

The U.S. Food and Drug Administration has released draft guidance describing “the agency’s view on whether regulated products contain nanomaterials or involve the application of nanotechnology”

Is FTC considering fast-track rulemaking to stop “pay-for-delay” drug deals?

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • June 16 2011

According to a news source, the Federal Trade Commission (FTC) may be planning to adopt a rule under expedited procedures to block patent settlements, known as “pay-for-delay” deals, between name-brand drug manufacturers and generic drug makers

FDA seizes probiotic products marketed as drugs

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • June 16 2011

The Food and Drug Administration (FDA) has reportedly seized probiotic products from a Minnesota-based company, alleging that they are being marketed as drugs

Review denied on failed challenge to stem cell research funding order

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • June 16 2011

The U.S. Supreme Court has reportedly denied a petition asking it to review a Fourth Circuit Court of Appeals ruling that human embryos and those considering adopting human embryos lack standing to challenge President Barack Obama’s executive order removing restrictions on funding for embryonic stem cell research

Current Search

Suggested Facets

Author

Jurisdiction

Workarea

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy